Selected research
Industry Research
Oncology Biosimilars Industry Research Report 2026
Market perspective
The global Oncology Biosimilars market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Oncology Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Oncology Biosimilars market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Oncology Biosimilars market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Oncology Biosimilars include Teva Pharmaceutical Industries Ltd, Sandoz International, Pfizer, STADA Arzneimittel AG, Intas Pharmaceuticals, Dr. Reddy’s Laboratories, Celltrion, Biocon and BIOCAD and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Oncology Biosimilars market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Oncology Biosimilars.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Oncology Biosimilars Market by Company
Teva Pharmaceutical Industries Ltd
Sandoz International
Pfizer
STADA Arzneimittel AG
Intas Pharmaceuticals
Dr. Reddy’s Laboratories
Celltrion
Biocon
BIOCAD
Apotex
Oncology Biosimilars Segment by Type
Hematopoietic Agents
Monoclonal Antibody
G-CSF
Others
Oncology Biosimilars Segment by Application
Hospital Pharmacy
Online Pharmacy
Retail Pharmacies
Oncology Biosimilars Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Biosimilars.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Oncology Biosimilars companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hematopoietic Agents
- Monoclonal Antibody
- G-CSF
- Others
Applications
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacies
Companies covered
- Teva Pharmaceutical Industries Ltd
- Sandoz International
- Pfizer
- STADA Arzneimittel AG
- Intas Pharmaceuticals
- Dr. Reddy’s Laboratories
- Celltrion
- Biocon
- BIOCAD
- Apotex
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Oncology Biosimilars by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Hematopoietic Agents
- 2.2.3 Monoclonal Antibody
- 2.2.4 G-CSF
- 2.2.5 Others
- 2.3 Oncology Biosimilars by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital Pharmacy
- 2.3.3 Online Pharmacy
- 2.3.4 Retail Pharmacies
- 2.4 Assumptions and Limitations
3 Oncology Biosimilars Breakdown Data by Type
- 3.1 Global Oncology Biosimilars Historic Market Size by Type (2021-2026)
- 3.2 Global Oncology Biosimilars Forecasted Market Size by Type (2027-2032)
4 Oncology Biosimilars Breakdown Data by Application
- 4.1 Global Oncology Biosimilars Historic Market Size by Application (2021-2026)
- 4.2 Global Oncology Biosimilars Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Oncology Biosimilars Market Perspective (2021-2032)
- 5.2 Global Oncology Biosimilars Growth Trends by Region
- 5.2.1 Global Oncology Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Oncology Biosimilars Historic Market Size by Region (2021-2026)
- 5.2.3 Oncology Biosimilars Forecasted Market Size by Region (2027-2032)
- 5.3 Oncology Biosimilars Market Dynamics
- 5.3.1 Oncology Biosimilars Industry Trends
- 5.3.2 Oncology Biosimilars Market Drivers
- 5.3.3 Oncology Biosimilars Market Challenges
- 5.3.4 Oncology Biosimilars Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Oncology Biosimilars Players by Revenue
- 6.1.1 Global Top Oncology Biosimilars Players by Revenue (2021-2026)
- 6.1.2 Global Oncology Biosimilars Revenue Market Share by Players (2021-2026)
- 6.2 Global Oncology Biosimilars Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Oncology Biosimilars Head Office and Area Served
- 6.4 Global Oncology Biosimilars Players, Product Type & Application
- 6.5 Global Oncology Biosimilars Manufacturers Established Date
- 6.6 Global Oncology Biosimilars Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Oncology Biosimilars Market Size (2021-2032)
- 7.2 North America Oncology Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Oncology Biosimilars Market Size by Country (2021-2026)
- 7.4 North America Oncology Biosimilars Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Oncology Biosimilars Market Size (2021-2032)
- 8.2 Europe Oncology Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Oncology Biosimilars Market Size by Country (2021-2026)
- 8.4 Europe Oncology Biosimilars Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Oncology Biosimilars Market Size (2021-2032)
- 9.2 Asia-Pacific Oncology Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Oncology Biosimilars Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Oncology Biosimilars Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Oncology Biosimilars Market Size (2021-2032)
- 10.2 South America Oncology Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Oncology Biosimilars Market Size by Country (2021-2026)
- 10.4 South America Oncology Biosimilars Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Oncology Biosimilars Market Size (2021-2032)
- 11.2 Middle East & Africa Oncology Biosimilars Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Oncology Biosimilars Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Oncology Biosimilars Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva Pharmaceutical Industries Ltd
- 12.1.1 Teva Pharmaceutical Industries Ltd Company Information
- 12.1.2 Teva Pharmaceutical Industries Ltd Business Overview
- 12.1.3 Teva Pharmaceutical Industries Ltd Revenue in Oncology Biosimilars Business (2021-2026)
- 12.1.4 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Product Portfolio
- 12.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 12.2 Sandoz International
- 12.2.1 Sandoz International Company Information
- 12.2.2 Sandoz International Business Overview
- 12.2.3 Sandoz International Revenue in Oncology Biosimilars Business (2021-2026)
- 12.2.4 Sandoz International Oncology Biosimilars Product Portfolio
- 12.2.5 Sandoz International Recent Developments
- 12.3 Pfizer
- 12.3.1 Pfizer Company Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Revenue in Oncology Biosimilars Business (2021-2026)
- 12.3.4 Pfizer Oncology Biosimilars Product Portfolio
- 12.3.5 Pfizer Recent Developments
- 12.4 STADA Arzneimittel AG
- 12.4.1 STADA Arzneimittel AG Company Information
- 12.4.2 STADA Arzneimittel AG Business Overview
- 12.4.3 STADA Arzneimittel AG Revenue in Oncology Biosimilars Business (2021-2026)
- 12.4.4 STADA Arzneimittel AG Oncology Biosimilars Product Portfolio
- 12.4.5 STADA Arzneimittel AG Recent Developments
- 12.5 Intas Pharmaceuticals
- 12.5.1 Intas Pharmaceuticals Company Information
- 12.5.2 Intas Pharmaceuticals Business Overview
- 12.5.3 Intas Pharmaceuticals Revenue in Oncology Biosimilars Business (2021-2026)
- 12.5.4 Intas Pharmaceuticals Oncology Biosimilars Product Portfolio
- 12.5.5 Intas Pharmaceuticals Recent Developments
- 12.6 Dr. Reddy’s Laboratories
- 12.6.1 Dr. Reddy’s Laboratories Company Information
- 12.6.2 Dr. Reddy’s Laboratories Business Overview
- 12.6.3 Dr. Reddy’s Laboratories Revenue in Oncology Biosimilars Business (2021-2026)
- 12.6.4 Dr. Reddy’s Laboratories Oncology Biosimilars Product Portfolio
- 12.6.5 Dr. Reddy’s Laboratories Recent Developments
- 12.7 Celltrion
- 12.7.1 Celltrion Company Information
- 12.7.2 Celltrion Business Overview
- 12.7.3 Celltrion Revenue in Oncology Biosimilars Business (2021-2026)
- 12.7.4 Celltrion Oncology Biosimilars Product Portfolio
- 12.7.5 Celltrion Recent Developments
- 12.8 Biocon
- 12.8.1 Biocon Company Information
- 12.8.2 Biocon Business Overview
- 12.8.3 Biocon Revenue in Oncology Biosimilars Business (2021-2026)
- 12.8.4 Biocon Oncology Biosimilars Product Portfolio
- 12.8.5 Biocon Recent Developments
- 12.9 BIOCAD
- 12.9.1 BIOCAD Company Information
- 12.9.2 BIOCAD Business Overview
- 12.9.3 BIOCAD Revenue in Oncology Biosimilars Business (2021-2026)
- 12.9.4 BIOCAD Oncology Biosimilars Product Portfolio
- 12.9.5 BIOCAD Recent Developments
- 12.10 Apotex
- 12.10.1 Apotex Company Information
- 12.10.2 Apotex Business Overview
- 12.10.3 Apotex Revenue in Oncology Biosimilars Business (2021-2026)
- 12.10.4 Apotex Oncology Biosimilars Product Portfolio
- 12.10.5 Apotex Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst